(Z)-3-甲氧基-N-甲基-N-苯乙烯基苯甲酰胺及其在制备抗炎药物中的应用
By regulating signal transduction pathways and inhibiting inflammatory responses through the compound (Z)-3-methoxy-N-methyl-N-styrenebenzamide, the problem of inhibiting the expression of IL-6 and IL-1β in existing technologies has been solved, thus achieving effective treatment for lung injury and chronic obstructive pulmonary disease.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- INST OF ZOOLOGY GUANGDONG ACAD OF SCI
- Filing Date
- 2022-11-28
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies are insufficient to effectively suppress inflammatory responses in respiratory diseases such as pneumonia and chronic obstructive pulmonary disease, especially the expression of IL-6 and IL-1β, leading to lung damage and other complications.
A compound (Z)-3-methoxy-N-methyl-N-styrenebenzamide was developed to inhibit the accumulation of inflammatory cells and the release of cytokines by regulating signaling pathways such as MAPK and NF-κB, thereby reducing the production of pro-inflammatory mediators and achieving dose-dependent inhibition of IL-6 and IL-1β expression.
It effectively reduces the level of inflammatory factors, providing a new drug approach for treating lung injury and chronic obstructive pulmonary disease, and inhibiting the occurrence and development of inflammatory responses.
Smart Images
Figure CN118084693B_ABST